Andere Sprachen Simcere Pharmaceutical Group Limited

Aktien

A2QD9S

HK0000658531

2096

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:20 26.04.2024			% 5 Tage	% 1. Jan.
5,3 ^HKD	+1,15 %		+2,91 %	-21,25 %

25.04.	Simcere Pharmaceutical' Gewinn sinkt 2023 um 23	MT
10.04.	Krebsmedikament von Simcere Pharmaceutical erhält Fast Track Designation von der US FDA	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Simcere Pharmaceutical’ Profit Down 23% in 2023	25.04.
Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA	10.04.
Simcere Pharmaceutical Group Limited Announces SIM0500 for Injection (a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody) Receives Fast Track Designation by the U.S. Food and Drug Administration	09.04.
Simcere Pharmaceutical's 2023 Profit Falls, Misses Estimates; Shares Rise 3%	21.03.
Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024	20.03.
Simcere Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	20.03.
Simcere Pharmaceutical Group's Cancer Drug NDA Accepted by Chinese Regulator	18.03.
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China	15.03.
Simcere Pharmaceutical Group's Cancer Drug Gets China Nod for Clinical Trials	13.03.
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration	12.03.
Simcere Pharmaceutical Group's New Anti-Cancer Drug Gets Clinical Trials Approval from the FDA	11.03.
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500	10.03.
Simcere Pharmaceutical Group Limited Announces Findings of A Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in Jama	21.02.
Simcere Pharma's Ischemic Stroke Treatment Results Published in US Neurology Journal	20.02.
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023	19.02.
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%	19.02.
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	18.02.
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19	18.01.
Simcere Pharma Unit's Shareholders Approve Order Collection Agreement	18.01.
China Grants Clinical Trial Approval for Simcere Pharmaceutical's Anti-Tumor Medication	15.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Simcere Pharmaceutical Group Limited

Aktien

A2QD9S

HK0000658531

2096

Andere Sprachen

Filter